Jun 22
Every few years, the clinical research industry rallies around a new wave of innovation. From decentralised trials and digital biomarkers to AI driven automation, each wave brings genuine capability andpromise.
Read the full article featuring Kelsey Jakee on page 38 here.
Related Blog Posts
2026 DIA Global Annual Meeting: What the FDA’s Real-Time Data Push Actually Means for Sponsors and CROs
In this video interview from the 2026 DIA Global Annual Meeting, Kevin Bugin, head of global regulatory policy and intelligence at Amgen and executive sponsor of TransCelerate’s Embedded Pragmatic Trials initiative, reframes the FDA’s continuous review expectations around real-time evidence generation and explains why quality by design—not data cleanup—is what regulators are now demanding. Watch…
Why 2026 could be a turning point for patient-focused trials
The clinical research ecosystem has spent more than a decade saying the right things about patient engagement. Health authorities, patient groups, sponsors, academic institutions, and a host of life science companies have all committed — publicly and repeatedly — to making it a priority. And yet the collective efforts across these stakeholders have remained fragmented.…
What happens when protocol data finally flows
Clinical research has no shortage of technology. What it lacks is the ability to scale in ways that allow information to flow automatically across systems and support digitally enabled workflows for critical stakeholders. Read the full article featuring Rob DiCicco from Clinical Trials Arena here.